Recent Price Movement and Market Context
On 27 Feb 2026, Epigral Ltd’s share price touched an intraday low of Rs.901.6, closing with a day change of -2.25%. This decline extended a four-day losing streak during which the stock has fallen by 6.08%. The stock’s performance today lagged behind the Specialty Chemicals sector by 1.18%, underscoring relative weakness amid a broadly negative market environment. The Sensex itself declined by 0.75%, closing at 81,632.67 after a flat opening, indicating a cautious market mood.
Epigral’s share price is currently trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages. This technical positioning highlights sustained downward momentum and a lack of near-term price support.
Long-Term Performance and Valuation Metrics
Over the past year, Epigral Ltd’s stock has delivered a negative return of 44.14%, a stark contrast to the Sensex’s positive 9.41% gain over the same period. The stock’s 52-week high was Rs.2,114.3, indicating a substantial erosion in market value. This underperformance extends beyond the last year, with the stock lagging the BSE500 index over the last three years, one year, and three months.
Despite the price decline, the company maintains a relatively strong management efficiency profile, with a return on capital employed (ROCE) of 23.19%. The debt servicing capacity is also robust, evidenced by a low Debt to EBITDA ratio of 1.34 times. Valuation metrics show an enterprise value to capital employed ratio of 1.7, which is considered very attractive and suggests the stock is trading at a discount relative to its peers’ historical valuations.
This week's disclosed pick, a Large Cap from NBFC, comes with precise Target Price and analysis. Check if you're positioned right for this opportunity!
- - Precise target price set
- - Weekly selection live
- - Position check opportunity
Financial Performance and Profitability Trends
Epigral Ltd’s financial results have shown mixed signals. The company’s operating profit has grown at a modest annual rate of 5.77% over the last five years, reflecting subdued long-term growth. However, recent quarterly results have been less favourable. The Profit Before Depreciation, Interest, and Taxes (PBDIT) for the latest quarter stood at Rs.102.74 crores, marking the lowest level recorded.
Interest expenses for the nine months ended December 2025 increased sharply by 43.93%, reaching Rs.56.16 crores. Concurrently, the quarterly Profit After Tax (PAT) declined by 61.1% compared to the previous four-quarter average, falling to Rs.39.11 crores. These figures indicate pressure on profitability and rising financing costs.
Comparative Sector and Market Position
Within the Specialty Chemicals sector, Epigral’s performance contrasts with some indices such as the S&P BSE Oil & Gas, which hit a new 52-week high on the same day. The Sensex’s 50-day moving average remains above its 200-day moving average, signalling a generally positive medium-term market trend, which Epigral has not mirrored.
The company’s majority ownership remains with promoters, maintaining stable control despite the stock’s price volatility.
Epigral Ltd or something better? Our SwitchER feature analyzes this small-cap Specialty Chemicals stock and recommends superior alternatives based on fundamentals, momentum, and value!
- - SwitchER analysis complete
- - Superior alternatives found
- - Multi-parameter evaluation
Summary of Key Metrics and Ratings
Epigral Ltd currently holds a Mojo Score of 31.0 with a Mojo Grade of Sell, upgraded from a previous Strong Sell rating on 26 Dec 2025. The company’s market capitalisation grade is 3, reflecting its small-cap status within the Specialty Chemicals sector. The stock’s recent price action and financial results have contributed to this rating adjustment.
While the company demonstrates strong management efficiency and a solid ability to service debt, the combination of declining profitability, rising interest costs, and sustained price weakness has weighed on investor sentiment and market valuation.
Conclusion
Epigral Ltd’s stock reaching a 52-week low of Rs.901.6 highlights a period of sustained price pressure amid challenging financial results and sector underperformance. The stock’s decline over the past year and recent quarterly earnings reflect a complex operating environment. Despite some positive indicators such as high ROCE and manageable debt levels, the overall trend remains subdued as the company navigates these headwinds.
Only Rs. 9,999 - Get MojoOne for 1 Year + 3 Months FREE (60% Off) Start Today
